CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.

Bommi-Reddy A. et al.

Therapeutic targeting of the estrogen receptor (ER) is a clinically validated approach for estrogen receptor positive breast cancer (ER+ BC), but sustained response is limited by acquired resistance. Targeting the transcriptional coactivators required for estrogen receptor activity represents an alternative approach that is not subject to the same limitations as targeting estrogen receptor itself. In this report we demonstrate that the acetyltransferase activity of coactivator paralogs CREBBP/EP300 represents a promising therapeutic target in ER+ BC. Using the potent and selective inhibitor CPI-1612, we show that CREBBP/EP300 acetyltransferase inhibition potently suppresses in vitro and in vivo growth of breast cancer cell line models and acts in a manner orthogonal to directly targeting ER. CREBBP/EP300 acetyltransferase inhibition suppresses ER-dependent transcription by targeting lineage-specific enhancers defined by the pioneer transcription factor FOXA1. These results validate CREBBP/EP300 acetyltransferase activity as a viable target for clinical development in ER+ breast cancer.

Microplex Library Preparation kit
iDeal ChIP-seq Kit for Histones
Chromatin Profiling (ChIP-seq) Services

Share this article

March, 2022


Products used in this publication

  • default alt
    ChIP-seq/ChIP-qPCR Profiling Service
  • ChIP kit icon
    iDeal ChIP-seq kit for Histones
  • Bioruptor Pico
    Bioruptor® Pico sonication device
  • some alt
    1.5 ml Bioruptor® Pico Microtubes with Caps
  • ChIP-seq Grade
    H3K9ac Antibody
  • cut and tag antibody icon
    H3K27ac Antibody
  • ChIP kit icon
    MicroPlex Library Preparation Kit v2 (12 indexes)


  • 64th ASH Annual Meeting and Exposition 2022
    New Orleans, Louisiana, USA
    Dec 10-Dec 13, 2022
 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics